ViiV Healthcare has reported that final data from the LATITUDE phase III trial show its long-acting injectable regimen, Cabenuva (cabotegravir + rilpivirine), maintained viral suppression more effectively than daily oral therapy in individuals with antiretroviral adherence difficulties. The results have been published in the New England Journal of Medicine.

• Efficacy outcome: At 48 weeks, participants who switched to long-acting cabotegravir + rilpivirine had a lower cumulative risk of regimen failure compared with those continuing oral treatment.
• Study specifics: LATITUDE was a phase III, open-label study involving adults with a history of challenges in taking daily antiretroviral therapy.
• Clinical context: Injection site reactions were among the most common adverse events, and additional studies are underway to further evaluate long-acting regimens.

This summary is based on a press release issued by ViiV Healthcare via GSK.